Bas Trietsch

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Epoch Biosciences, Inc. manufactures and develops molecular tools for genetic analysis. Its technology has numerous applications including the detection of inherited diseases and single nucleotide polymorphisms to identify individuals at risk for disease or adverse drug reactions and gene expression measurement. The company was founded in 1985 and is headquartered in Bothell, WA.

Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY.

Abeome Corp. operates as a biotechnology company. It develops therapeutic and diagnostic monoclonal antibodies (mAbs). The firm’s DiSH (Direct Selection of Hybridomas) technology offers a process for selecting and cloning desired hybridomas that produce antibodies with optimal binding characteristics. The company was founded by Richard B. Meagher in 2000 and is headquartered in Athens, GA.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.

GenPharm International, Inc. manufactures biopharmaceutical products. The company works towards the application of transgenic animal technology to the development of human antibody products, which are used for therapeutic uses. It was founded in 1988 and is located in San Jose, CA.

EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California.

Part of AstraZeneca PLC, Mogen International Nv is a Dutch company that specializes in medicinal chemicals and botanical products. The company is based in Leiden, the Netherlands. Mogen International was acquired by Zeneca Group Plc on May 01, 1997 for $74.96 million.

Aglaia Management BV is an independent venture capital investment firm headquartered in Bilthoven, the Netherlands. In 2003, Aglaia was co-founded by Mark Krul and Karl Rothweiler.

ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.

VitalneXt BV develops retails and manufactures products for healthy ageing. Its products include promanna, vital01 and other products. The firm develops products with evidence-based health benefits for the ageing population. It also develops new, proprietary, technologies, ingredients and products through its own network and through collaborations with the company's research partners. The company was founded by Rein Strijker in May 2013 and is headquartered in Amersfoort, the Netherlands.

Biosanapharma BV is a Dutch pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Leiden, Netherlands. The CEO of the company is Ard Tijsterman.

Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands.

Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety.

Pepscope BV is a company based in Utrecht, Netherlands that develops and provides advanced customer-focused protein analysis services and products. The Dutch company aims to make kinase inhibitors better therapeutics by providing unique insights into their functioning through quantitative profiling of the kinome in cells and tissues. Pepscope offers a unique, targeted mass-spectrometry-based, multiplexed, endogenous kinase activity profiling technology for clinical samples. Recently, Pepscope announced a 4.3-million-euro funding round to further develop and commercialize their lead product QuantaKinome™, which provides direct insights into the activities of hundreds of protein kinases simultaneously inside the cells of diseased tissues. Pepscope offers QuantaKinome™ to the pharmaceutical industry and academic researchers to improve the discovery and development of drugs. The company was founded by Jos Joore, Hans Brouwer, and Anna Ressa, with Anna Ressa serving as the CEO since incorporation.